`___________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`
`COALITION FOR AFFORDABLE DRUGS V LLC,
`Petitioner,
`
`v.
`
`BIOGEN MA INC.,
`Patent Owner.
`____________________________________________
`
`Case: IPR2015-01136
`U.S. Patent No. 8,399,514 B2
`____________________________________________
`
`
`
`PATENT OWNER’S EXHIBIT LIST
`(as of August 11, 2015)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibits
`Description
`Exhibit 2001 Hayman Capital Management, L.P. Form ADV Part 2A
`Brochure, June 1, 2015
`
`Exhibit 2002
`
`Investment Adviser Public Disclosure, Part 2 for Hayman
`Capital Management, L.P.,
`http://www.adviserinfo.sec.gov/iapd/content/viewform/adv/Sec
`tions/iapd_Adv2Brochures.aspx?ORG_PK=146896&RGLTR_
`PK=50000&STATE_CD=&FLNG_PK=034480240008017C01
`3E73700561A20D056C8CC0 (retrieved June 25, 2015).
`
`Exhibit 2003
`
`United States Securities and Exchange Commission Form D for
`Hayman Orange Fund SPC-Segregated Portfolio A, dated April
`9, 2015.
`
`Exhibit 2004 Restatement (Second) of Torts § 682 (1977)
`Exhibit 2005 Cartwright v. Wexler, Wexler & Heller, Ltd., 369 N.E.2d 185
`(Ill. App. Ct. 1977)
`Exhibit 2006 Lader v. Benkowitz, 188 Misc. 906, 66 N.Y.S.2d 713 (Sup. Ct.
`1946)
`
`Exhibit 2007
`157 Cong. Rec. S936-53 (daily ed. Feb. 28, 2011)
`Exhibit 2008 File Wrapper for U.S. Provisional Application No. 60/888,921,
`filed February 8, 2007
`Exhibit 2009 Final Office Action dated October 12, 2012, in U.S. Patent
`Application No. 13/372,426
`Exhibit 2010 Application Data Sheet and Inventor Declaration filed February
`13, 2012, for U.S. Patent Application No. 13/372,426
`
`Exhibit 2011
`
`Electronic Patent Application Fee Transmittal and
`Electronic Acknowledgement Receipt dated August 7, 2009,
`in U.S. Patent Application No. 12/526,296
`Exhibit 2012 Reply to Final Office Action filed December 12, 2012, in U.S.
`Patent Application No. 13/372,426
`
`
`
`1
`
`
`
`
`
`Exhibits
`
`Description
`
`Exhibit 2013
`
`Exhibit 2014
`
`Exhibit 2015
`
`Joseph A. DiMasi, Success rates for new drugs entering
`clinical testing in the United States, 58 CLIN. PHARMACOL.
`THER. 1 (1995)
`Joseph A. DiMasi, Risks in new drug development: Approval
`success rates for investigational drugs, 69 CLIN. PHARMACOL.
`THER. 297 (2001)
`Avanir Pharmaceuticals (AVNR), Crashes as Multiple Sclerosis
`Drug Fails Phase 2 Trial (December 11, 2013),
`http://www.biospace.com/News/avanir-pharmaceuticals-
`crashes-as-multiple/318325
`
`Exhibit 2016
`
`A. I. Graul et al., Overcoming Further Challenges in the
`Pharma/Biotech Industry: 2007 Update, 21 DRUG NEWS
`PERSPECT. 44 (2008)
`Exhibit 2017 A. I. Graul & J.R. Prous, Overcoming the Challenges in the
`Pharma/Biotech Industry, 20 DRUG NEWS PERSPECT. 57 (2007)
`Exhibit 2018 H.R. REP. NO. 112-98, pt. 1 (2011)
`
`Exhibit 2019 Ex parte McGaughey, 6 U.S.P.Q.2d 1334 (BPAI Mar. 4, 1988)
`Exhibit 2020 Ex parte Raychem Corp., 25 U.S.P.Q.2d 1265 (BPAI June 30,
`1992)
`
`Exhibit 2021
`
`Declaration of Richard A. Rudick, M.D. Under 37 C.F.R.
`§1.132 filed on August 3, 2012 in U.S. Patent Application No.
`13/372,426
`Exhibit 2022 Notice of Allowance and Fees Due dated December 26, 2012 in
`U.S. Patent Application No. 13/372,426
`
`Respectfully submitted,
`
`By: / Maureen D. Queler /
`Michael J. Flibbert, Reg. No. 33,234
`Maureen D. Queler, Reg. No. 61,879
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: August 11, 2015
`
`
`
`
`
`2
`
`
`
`
`
`
`
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner
`
`3
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that copies of the foregoing PATENT
`
`OWNER’S EXHIBIT LIST and Exhibits 2008-2022 were served on August 11,
`
`2015, via electronic mail directed to counsel of record for the Petitioner at the
`
`following:
`
`Robert W. Hahl
`Neifeld IP Law, PC, 4813-B
`Eisenhower Avenue, Alexandria, VA 22304
`rhahl@neifeld.com
`
`Robert Mihail
`Neifeld IP Law, PC, 4813-B
`Eisenhower Avenue, Alexandria, VA 22304
`rmihail@neifeld.com
`
`Petitioner has agreed to electronic service.
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Maureen D. Queler/
` Maureen D. Queler
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`
`
`
`
`
`
`Dated: August 11, 2015
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
